Mymd Pharmaceuticals (NASDAQ:QCLS) Downgraded by Wall Street Zen to Sell

Wall Street Zen cut shares of Mymd Pharmaceuticals (NASDAQ:QCLS) from a hold rating to a sell rating in a research report report published on Saturday morning.

Separately, Weiss Ratings began coverage on shares of Mymd Pharmaceuticals in a research report on Wednesday, May 13th. They issued a “sell (e+)” rating on the stock. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Mymd Pharmaceuticals Trading Up 4.3%

Shares of NASDAQ:QCLS opened at $2.92 on Friday. The stock has a 50-day simple moving average of $3.55. Mymd Pharmaceuticals has a 12-month low of $2.50 and a 12-month high of $12.24. The firm has a market cap of $12.18 million, a price-to-earnings ratio of -0.14 and a beta of 2.16.

Mymd Pharmaceuticals (NASDAQ:QCLS) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.19) EPS for the quarter.

Mymd Pharmaceuticals Company Profile

MyMD Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for immune-related and other serious diseases. The company has worked on product candidates designed to address conditions involving inflammation, immune system dysfunction, and age-related disease processes.

The company’s pipeline has included drug development programs in areas such as autoimmune and inflammatory disorders, with an emphasis on advancing compounds through preclinical and clinical evaluation.